Related Experiment Video
Updated: Jul 26, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?
Dea Metko1, Tiago Torres2, Ronald Vender3
1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Canada.
Abstract:
Over the past two decades, promising advancements have emerged in the field of psoriasis management. Most notably, highly effective targeted biologic therapies that offered significant breakthroughs in the management of psoriasis have been developed. One of the most challenging components of marketing and prescribing these biologic therapies has been in classifying them as immunomodulators or immunosuppressants. The purpose of this narrative review was to discuss the features that distinguish immunomodulators from immunosuppressants to successfully categorize the biologic therapies used for psoriasis management and subsequently enhance patient and physician understanding of the risks associated with the use of these drugs.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD